Baroness Brinton Portrait

Baroness Brinton

Liberal Democrat - Life peer

Became Member: 4th February 2011

Liberal Democrat Lords Spokesperson (Health)
1st Feb 2020 - 31st Dec 2022
Acting Leader, Liberal Democrats
13th Dec 2019 - 1st Jan 2020
Party Chair, Liberal Democrats
1st Jan 2015 - 1st Jan 2020
Equality Act 2010 and Disability Committee
11th Jun 2015 - 15th Mar 2016

Division Voting information

During the current Parliament, Baroness Brinton has voted in 544 divisions, and never against the majority of their Party.
View All Baroness Brinton Division Votes

Debates during the 2019 Parliament

Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.

Sparring Partners
Lord Bethell (Conservative)
(129 debate interactions)
Lord Kamall (Conservative)
(68 debate interactions)
Lord Markham (Conservative)
Parliamentary Under-Secretary (Department of Health and Social Care)
(61 debate interactions)
View All Sparring Partners
Department Debates
Department of Health and Social Care
(287 debate contributions)
Home Office
(82 debate contributions)
Leader of the House
(63 debate contributions)
Cabinet Office
(45 debate contributions)
View All Department Debates
Legislation Debates
Victims and Prisoners Bill 2022-23
(29,798 words contributed)
Health and Care Act 2022
(18,884 words contributed)
Schools Bill [HL] 2022-23
(14,129 words contributed)
View All Legislation Debates
View all Baroness Brinton's debates

Lords initiatives

These initiatives were driven by Baroness Brinton, and are more likely to reflect personal policy preferences.

1 Bill introduced by Baroness Brinton

Baroness Brinton has not co-sponsored any Bills in the current parliamentary sitting

Latest 6 Written Questions

(View all written questions)
Written Questions can be tabled by MPs and Lords to request specific information information on the work, policy and activities of a Government Department
18th Jan 2022
To ask Her Majesty's Government how many people in the UK are immunocompromised or immunosuppressed and classified as (1) severely clinically extremely vulnerable, and (2) clinically extremely vulnerable excluding those who are severely clinically extremely vulnerable.

The success of the COVID-19 vaccination programme has meant that shielding and identifying people as clinically extremely vulnerable (CEV) are no longer necessary. This is because the majority of those previously considered to be CEV will benefit from the COVID-19 vaccine. However, there remains a smaller number of people who, in spite of vaccination, are at higher risk of serious illness from COVID-19. This is due to a weakened immune system or specific other medical condition, which means they require enhanced protections such as those offered by antivirals and therapeutics, additional vaccinations and potentially other non-clinical interventions.

Within this smaller group, approximately 1.3 million people have been identified as potentially eligible for Antivirals, and Neutralising Monoclonal Antibodies, as non-hospitalised treatments, and approximately 0.5 million people in England have been identified as severely immunosuppressed and therefore eligible for a third primary COVID-19 vaccine dose.

28th Jul 2020
To ask Her Majesty's Government what estimate they have made of the number of alcohol-related ambulance service callouts in each of the last four years in England.

The information requested is not centrally collected.

18th May 2020
To ask Her Majesty's Government whether they have placed a bulk order for the Roche Elecsys Anti-SARS-CoV-2 antibody tests; and if so, (1) how many tests were ordered and at what cost, and (2) the quantities expected to arrive in the UK by (a) the end of May (b) mid June and (c) the end of June.

We have signed contracts to supply over 10 million tests from Roche and Abbott in the coming months. We have agreed these contracts with two suppliers whose assays have been evaluated by Public Health England and continue to engage with other companies to establish further agreements to meet our testing strategy. These contracts will secure a significant volume to meet the United Kingdom’s testing plans. Further details are commercially sensitive.

18th May 2020
To ask Her Majesty's Government when they first became aware of the Roche Elecsys Anti-SARS-CoV-2 antibody test; what discussions they held with the European Medicines Agency and stakeholders in Germany about their trials and approval processes; and why they decided to run their own separate trials and approval process.

Public Health England (PHE) were asked to review all major suppliers of assays for National Health Service use, including the Roche Elecsys Anti-SARS-CoV-2 antibody test, in order to limit the amount of on-site evaluation each facility has to perform.

PHE is familiar with the processes involved in European Medicine Agency registration. No discussions have been held with stakeholders in Germany about their trial and approvals processes.

22nd Nov 2022
To ask His Majesty's Government what are the “purposes” currently active in the “Purpose-Based Access Control” feature in Palantir’s Foundry software in use in the Home Office.

The Home Office does not use Palantir Foundry software and therefore cannot provide information on the Purpose-Based Access Controls.

Lord Sharpe of Epsom
Parliamentary Under-Secretary (Home Office)
22nd Nov 2022
To ask His Majesty's Government what are the “purposes” currently active in the “Purpose-Based Access Control” feature in Palantir’s Foundry software in use in the Department for Levelling Up, Housing and Communities.

Being assigned a 'purpose' (now known as a 'project') gives a Foundry user access to different data on Homes for Ukraine, depending on their role. For privacy and security reasons, the access rights for users is carefully controlled. Foundry does not hold data not related to Homes for Ukraine and is not used for any other purpose.

Baroness Scott of Bybrook
Parliamentary Under Secretary of State (Department for Levelling Up, Housing and Communities)